Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase CDK2]
Substrate: RB1

Description: Retinoblastoma-associated protein (PP110) (P105-RB) (RB).

Ensembl ID: ENSG00000139687

UniprotKB/SwissProt: RB_HUMAN (P06400)

Function: Key regulator of entry into cell division that acts as a tumor suppressor. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases SUV39H1, SUV420H1 and SUV420H2, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Also acts as a transcription repressor of E2F target genes by recruiting chromatin-modifying enzymes to promoters. Inhibits the intrinsic kinase activity of TAF1. Forms a complex with adenovirus E1A and with SV40 large T antigen. May bind and modulate functionally certain cellular proteins with which T and E1A compete for pocket binding.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Nucleus.
PDB:1AD6
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of RB1

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1RB1RB_HUMANT5-MPPK T PRKTA 33.81%CDK4 HPRD:01574(in vitro)  ViewAnalyzing
2RB1RB_HUMANS230YFIKL S PPMLL 23.19%CDK2 HPRD:01574(in vitro)  ViewAnalyzing
3RB1RB_HUMANS249IPING S PRTPR 13.51%CDC2 Swiss-Prot 55.0   ViewAnalyzing
4RB1RB_HUMANS249IPING S PRTPR 13.51%CDC2 HPRD:01574(in vivo)  ViewAnalyzing
5RB1RB_HUMANS249IPING S PRTPR 13.51%CDK_group Phospho.ELM 7.0 ViewAnalyzing
6RB1RB_HUMANT252NGSPR T PRRGQ 25.24%CDC2 Swiss-Prot 55.0   ViewAnalyzing
7RB1RB_HUMANT252NGSPR T PRRGQ 25.24%CDK_group Phospho.ELM 7.0 ViewAnalyzing
8RB1RB_HUMANT252NGSPR T PRRGQ 25.24%CDC2 HPRD:01574(in vivo)  ViewAnalyzing
9RB1RB_HUMANT356FETQR T PRKSN 20.02%CDK4 HPRD:01574(in vitro)  ViewAnalyzing
10RB1RB_HUMANT373VIPPH T PVRTV 29.29%CDK_group Phospho.ELM 7.0 ViewAnalyzing
11RB1RB_HUMANT373VIPPH T PVRTV 29.29%CDC2 HPRD:01574(in vivo)  ViewAnalyzing
12RB1RB_HUMANT373VIPPH T PVRTV 29.29%CDC2 Swiss-Prot 55.0   ViewAnalyzing
13RB1RB_HUMANS567AWLSD S PLFDL 21.81%CDK2 HPRD:01574(in vitro)  ViewAnalyzing
14RB1RB_HUMANS608ADMYL S PVRSP 12.12%CDK2 HPRD:01574(in vitro)  ViewAnalyzing
15RB1RB_HUMANS612LSPVR S PKKKG 41.11%CDK2 HPRD:01574(in vitro)  ViewAnalyzing
16RB1RB_HUMANS780RPPTL S PIPHI 24.22%CDK4 HPRD:01574(in vitro;in vivo)  ViewAnalyzing
17RB1RB_HUMANS780RPPTL S PIPHI 24.22%P30279(Cyclin D2) HPRD:01574(in vitro;in vivo) ViewAnalyzing
18RB1RB_HUMANS788PHIPR S PYKFP 27.51%CDK4 HPRD:01574(in vitro)  ViewAnalyzing
19RB1RB_HUMANS795YKFPS S PLRIP 28.35%CDK4 HPRD:01574(in vitro)  ViewAnalyzing
20RB1RB_HUMANS807GNIYI S PLKSP 13.75%CDC2 Swiss-Prot 55.0   ViewAnalyzing
21RB1RB_HUMANS807GNIYI S PLKSP 13.75%CDK_group Phospho.ELM 7.0 ViewAnalyzing
22RB1RB_HUMANS807GNIYI S PLKSP 13.75%CDC2 HPRD:01574(in vivo)  ViewAnalyzing
23RB1RB_HUMANS811ISPLK S PYKIS 40.94%CDC2 Swiss-Prot 55.0   ViewAnalyzing
24RB1RB_HUMANS811ISPLK S PYKIS 40.94%CDK_group Phospho.ELM 7.0 ViewAnalyzing
25RB1RB_HUMANS811ISPLK S PYKIS 40.94%CDC2 HPRD:01574(in vivo)  ViewAnalyzing
26RB1RB_HUMANT821SEGLP T PTKMT 48.94%CDK2 HPRD:01574(in vitro)  ViewAnalyzing
27RB1RB_HUMANT826TPTKM T PRSRI 19.67%CDK4 HPRD:01574(in vitro)  ViewAnalyzing
28RB1RB_HUMANT826TPTKM T PRSRI 19.67% Swiss-Prot 55.0 (Similarity)View